ArticleLancet (London, England)2020
Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry.
Article in Lancet (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 444 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
444 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Extracorporeal membrane oxygenation initiation timing and prognosis: a systematic review and meta-analysis.BMC cardiovascular disorders · 2026Pooled it
- Rehabilitation and Social Determinants of Health in Critical Illness Recovery Literature: A Systematic Review.Critical care explorations · 2024Pooled it
- Comparison of venovenous extracorporeal membrane oxygenation, prone position and supine mechanical ventilation for severely hypoxemic acute respiratory distress syndrome: a network meta-analysis.Intensive care medicine · 2024Pooled it
- Neurological Complications of the Lower Extremities After Femoral Cannulated Extracorporeal Membrane Oxygenation: A Systematic Review.Journal of intensive care medicine · 2024Pooled it
- CytoSorb in patients with coronavirus disease 2019: A rapid evidence review and meta-analysis.Frontiers in immunology · 2023Pooled it
- Temporary mechanical circulatory support for COVID-19 patients: A systematic review of literature.Artificial organs · 2022Pooled it
- Pre-ECMO characteristics, organ dysfunction and exploratory mortality prediction in COVID-19 versus non-COVID-19 ARDS treated with veno-venous ECMO: a retrospective cohort study.BMC anesthesiology · 2026Article
- 60 years of ARDS and the evolution of extracorporeal lung support - from ECMO to ECCOIntensive care medicine · 2026Review
- The Acute Respiratory Distress Syndrome (ARDS): epidemiology, etiology, molecular mechanisms, diagnosis and therapeutic strategies.Molecular biomedicine · 2026Review
- Review
- Metabolomic Signatures of Biotrauma Associated with Mortality in ICU Patients Requiring Invasive Mechanical Ventilation and ECMO.Metabolites · 2026Article
- Article
- Patient outcomes following extracorporeal membrane oxygenation support for severe COVID-19 acute respiratory distress syndrome.Proceedings (Baylor University. Medical Center) · 2026Article
- Tracheostomy During Extracorporeal Membrane Oxygenation in Adult ICU Patients: A Systematic Review.Journal of clinical medicine · 2026Review
- Article
- Psychosocial outcome of COVID-19 patients requiring ventilation after ECMO versus long-term mechanical ventilation.Frontiers in cardiovascular medicine · 2026Article
- Case Report: Prolonged extracorporeal membrane oxygenation as a deliberate operative adjunct for tracheobronchial reconstruction in a child with invasive aspergillosis.Frontiers in pediatrics · 2026Article
- A Novel Method for Predicting Recirculation by Sweep-Gas Control in Extracorporeal Membrane Oxygenation.Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia · 2026Article
- Prevalence and microbiological profile of septic complications following ECMO decannulation: a prospective single-center study.Scientific reports · 2025Article
- Interleukin-6-to-lymphocyte count ratio in the prognosis of moderate-to-severe acute respiratory distress syndrome supported by venovenous extracorporeal membrane oxygenation: a single-center retrospective study.Journal of thoracic disease · 2025Article
384 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
20 authors.
Funding
Abstract
backgroundMultiple major health organisations recommend the use of extracorporeal membrane oxygenation (ECMO) support for COVID-19-related acute hypoxaemic respiratory failure. However, initial reports of ECMO use in patients with COVID-19 described very high mortality and there have been no large, international cohort studies of ECMO for COVID-19 reported to date.
methodsWe used data from the Extracorporeal Life Support Organization (ELSO) Registry to characterise the epidemiology, hospital course, and outcomes of patients aged 16 years or older with confirmed COVID-19 who had ECMO support initiated between Jan 16 and May 1, 2020, at 213 hospitals in 36 countries. The primary outcome was in-hospital death in a time-to-event analysis assessed at 90 days after ECMO initiation. We applied a multivariable Cox model to examine whether patient and hospital factors were associated with in-hospital mortality.
findingsData for 1035 patients with COVID-19 who received ECMO support were included in this study. Of these, 67 (6%) remained hospitalised, 311 (30%) were discharged home or to an acute rehabilitation centre, 101 (10%) were discharged to a long-term acute care centre or unspecified location, 176 (17%) were discharged to another hospital, and 380 (37%) died. The estimated cumulative incidence of in-hospital mortality 90 days after the initiation of ECMO was 37·4% (95% CI 34·4-40·4). Mortality was 39% (380 of 968) in patients with a final disposition of death or hospital discharge. The use of ECMO for circulatory support was independently associated with higher in-hospital mortality (hazard ratio 1·89, 95% CI 1·20-2·97). In the subset of patients with COVID-19 receiving respiratory (venovenous) ECMO and characterised as having acute respiratory distress syndrome, the estimated cumulative incidence of in-hospital mortality 90 days after the initiation of ECMO was 38·0% (95% CI 34·6-41·5).
interpretationIn patients with COVID-19 who received ECMO, both estimated mortality 90 days after ECMO and mortality in those with a final disposition of death or discharge were less than 40%. These data from 213 hospitals worldwide provide a generalisable estimate of ECMO mortality in the setting of COVID-19.
fundingNone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.